Faheem Hasnain
Co-Founder, CEO, President & ChairmanMr. Faheem Hasnain is Executive Chairman of Aspen Neuroscience, Inc. from August 2026 and was its Chairman from April 2020. Mr. Hasnain has been Chief Executive Officer and President at Gossamer Bio, Inc. since November 16, 2020. He served as Executive Advisor at Vertex Ventures HC since joining the firm on October 29, 2020. He serves as Venture Advisor at Vertex Ventures HC. He serves as Independent Director of Panacea Acquisition Corp. since July 2020. Mr. Hasnain is the Co-Founder and Chairman of Gossamer Bio, Inc. since October 2015 and also served as its Chief Executive Officer from October 2015 to July 2018 and Executive Chairman from July 2018 to June 2019. Mr. Hasnain served as Chairman of Mirati Therapeutics, Inc. since February 15, 2019 until January 23, 2024 and also served as its Lead Independent Director since 2022 until January 23, 2024. He serves as Chairman at Sling Therapeutics, Inc. He serves as Independent Director of Kura Oncology, Inc. since April 2015 and serves as its Lead Independent Director since March 2020. Mr. Hasnain served as President, Chief Executive Officer and a Director of Receptos, Inc. from November 2010 until its acquisition by Celgene Corporation in August 27, 2015. Prior to joining Receptos, Mr. Hasnain was the President and Chief Executive Officer and a Director of Facet Biotech Corporation. Mr. Hasnain was the President and Chief Executive Officer of AbbVie Biotherapeutics Inc. and served as its Director since November 2008. He held that position from December 2008 until the company’s acquisition by Abbott Laboratories in April 2010. Previously, Mr. Hasnain was President, Chief Executive Officer and a Director of PDL BioPharma, Inc. from October 01, 2008 until Facet Biotech was spun off from PDL BioPharma in December 18, 2008. From October 2004 to September 2008, Mr. Hasnain served at Biogen Idec Inc., most recently as Executive Vice President in charge of the oncology/rheumatology strategic business unit. Prior to Biogen Idec, Mr. Hasnain held roles with Bristol-Myers Squibb, where he was President of the Oncology Therapeutics Network Corporation and at GlaxoSmithKline and its predecessor organizations. He served as Director at Ipsen Biopharmaceuticals, Inc. since February 2008. He previously served as Chairman of the Board of Ambit Biosciences Corporation from November 2010 to November 10, 2014 and served as its Director from October 2010 to November 10, 2014. He served as a Member of the Board of Directors of Tercica, Inc., Aragon Pharmaceuticals, Inc. since August 28, 2012, Seragon Pharmaceuticals, Inc. and Pernix Sleep, Inc. since September 21, 2010. He served as Director at Vital Therapies, Inc. since August 11, 2016 and served as its Chairman and Lead Director since September 2017. He served as Director at Somaxon Pharmaceuticals Inc. He had been Chairman of the Board of Sente, Inc. since 2008, Chairman of the Board of Tocagen Inc. since October 2014 and a Member of the Board of Overseers of Scripps Research Institute since 2018. Mr. Hasnain received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada. Mr. Hasnain serves as Member of Advisory Board at Abintus Bio Inc.
公司职务
- 公司名称Gossamer Bio, Inc.股票代码GOSS职务Co-Founder, CEO, President & Chairman共事同僚
- BGBryan GiraudoCOO & CFO
- RPRobert Paul SmithChief Commercial Officer
- CWChristian WaageExecutive Vice President, Technical Operations & General Counsel
- JAJeanine AnthonySenior Vice President of Marketing
- RJRussell J. CoxIndependent Director
- SMSandra MilliganIndependent Director
- SDSkye DrynanIndependent Director
- TOThomas O. DanielLead Independent Director
- 公司名称Aspen Neuroscience, Inc.股票代码ASPE职务Executive Chairman
